Insights

The New Gold Standard of Drug Commercialization

Manufacturers spend >$125MM over three years leading up to launch, yet 66% of drugs don’t meet launch expectations. An unpredictable landscape, coupled with inevitable industry pressures, is forcing manufacturers to seek a more complete commercialization approach…

Compliance – The Competitive Differentiator to Commercialization: An Integrated Model Setting the New Global Standard

The Compliance experts at EVERSANA prove how integrated life science compliance has earned its seat at the table by demonstrating the value of increasing data-driven and technology-infused competitiveness in the successful commercialization of a new-age biopharma…

A Predictive Analytics and Machine Learning Approach to Improving Hub Performance and Patient Outcomes

Today we have access to more data, from more sources than we could ever dream possible. Living in a digital world, we increasingly need the ability to efficiently and effectively process this data for insights and…

Why are We Settling for Mediocre Patient Services Programs?

Patient Services Programs Are Falling Short To give credit where credit is due, pharmaceutical manufacturers make a tremendous – and well-intended – effort to alleviate the product access obstacles and burdens patients and providers often endure…

Articles

High-Efficiency Commercialization for High-Science Brands

High-stake or complex therapies, such as cell and gene therapies, immunotherapies and RNA interference (RNAi), have the potential to change the course of treatment for cancer patients and patients with rare diseases. But first, pharma companies must work with providers to navigate patient access complications…

Leading the Way in Digital Health With Tech-Driven Clinical Pathways

Digital health technologies have become integral to patient care since the beginning of the COVID-19 pandemic and will remain essential healthcare tools. As many patients and healthcare providers are embracing digital health devices, clinical pathway developers have…

Patient Empowerment on the Rise with Health Consumerism

There’s no question that the pharma industry is evolving, and so are company relationships with patients as health consumerism gains popularity.  While the COVID-19 pandemic created an immediate need for telehealth options, patients are seeing their own personal needs for customized healthcare options overall. Today’s…

How Does the Biden Administration Want to ‘Take on Pharma?’

Throughout his campaign, Biden has promised to, once in office, expand access to health care through the “Biden Plan,” an evolution of former President Barack Obama’s Affordable Care Act, dubbed “Obamacare,” while “taking on big pharma”…

Achieve Price and Access Launch Excellence in a Disrupted World

With the U.S. election behind us, the soaring costs of U.S. healthcare have become a priority for politicians—in particular, the cost of prescription drugs. Some proposed solutions involve external reference pricing from comparable countries and limiting drug price increases. These anticipated changes in U.S. pricing policy, coupled with the downward pressure on…

Insights From Dreamforce 2020 Panel: End-To-End Patient Engagement

EVERSANA was proud to participate in this year’s brand-new session “End-To-End Patient Engagement: From Clinical Trials Through Patient Support Programs.“ Bhaskar Sambasivan, Chief Strategy Officer and President of Patient Services, provided valuable insight into the emerging…

Insights From Trade & Channel Strategies Conference 2020

Now more than ever, pharma manufacturers need to break the cycle of supply chain complexity to better connect patients to therapy. On Tuesday, December 1, EVERSANA’s Scot Buchanan moderated the panel “Emerging and Future Trends in Channel…

DSCSA Guidelines – Best Practices for Compliance and Supply Chain Integration

On November 27, 2023, all drug manufacturers must participate in an electronic package-level traceability system, commonly known as the “interoperability” requirement. EVERSANA is equipped to help manufacturers navigate these new guidelines and apply best practices. Let’s…

EVERSANA Receives PM360 Innovations Award for Seamlessly Disrupting Commercialization

EVERSANA’s end-to-end commercialization solution is reimagining traditional pharmaceutical commercialization models for the first time by breaking down industry service silos with integrated approaches and advanced technologies.   PM360‘s Annual Innovation Issue was established in 2011 to provide pharma with its first-ever guide to the life sciences industry’s…

COVID-19 Vaccine Safety Briefing Report

As the world awaits the fast-approaching rollout of an approved COVID-19 vaccine, developing the planning to order, distribute and track COVID-19 vaccines in the United States and globally presents an unprecedented challenge. The Food and Drug…